THE INFLUENCE OF EXOCRINE PANCREATIC INSUFFICIENCY ON THE LIPID PROFILE OF PATIENTS WITH PRIMARY OSTEOARTHRITIS
DOI:
https://doi.org/10.11603/mcch.2410-681X.2023.i4.14180Keywords:
primary osteoarthritis, exocrine pancreatic insufficiency, type 2 diabetes mellitus, chronic pancreatitis, chronic non-calculous cholecystitis, functional diseases of the gallbladder and biliary system, chronic gastritis, chronic duodenitis, lipidogramAbstract
Introduction. An increase in the level of cholesterol, a decrease in high-density lipoprotein (HDL), an increase in the level of triglycerides, and the presence of a high level of C-reactive protein are risk factors in primary OA contributing to the progression of this disease and worsen the prognosis, especially in conditions of comorbidity with diseases that are accompanied by exocrine pancreatic insufficiency (EPI).
The aim of the study – to analyze the changes in the lipid profile of patients with primary OA under conditions of comorbidity with diseases of the gastrointestinal tract in comorbidity with exocrine pancreatic insufficiency.
Research Methods. 304 patients with primary OA in comorbidity with diseases of the gastrointestinal tract accompanied by non-exacerbation EPI were examined. The comparison group consisted of 30 practically healthy individuals who did not have clinical, anamnestic, or instrumental signs of diseases of the gastrointestinal tract and joints. The lipid profile (total cholesterol, triglycerides, LDL, HDL) was determined by the enzyme-colorimetric method using appropriate test systems.
Results and Discussion. When analyzing lipidogram indicators in the studied groups, a statistically significant difference in the levels of these indicators was found (р˂0.05), which indicates the influence of comorbid gastroenterological pathology on the formation of dyslipidemic changes in primary OA.
Conclusion. Post hoc analysis revealed the following ranking of comorbid gastroenterological pathology accompanied by ECP in primary OA according to indicators of lipidogram, starting with the most profound changes: T2DM ˃ CP ˃ chronic non-calculous cholecystitis and functional diseases of the gallbladder and biliary system ˃ chronic gastroduodenitis (p˂0.05).
References
Robinson, W.H., Lepus, C.M., Wang, Q., Raghu, H., Mao, R., Lindstrom, T. M., & Sokolove, J. (2016). Low-grade inflammation as a key mediator of the pathogenesis of osteoarthritis. Nature reviews. Rheumatology, 12 (10), 580-592. https://doi.org/10.1038/nrrheum.2016.136 DOI: https://doi.org/10.1038/nrrheum.2016.136
Xiong, J., Long, J., Chen, X., Li, Y., & Song, H. (2020). Dyslipidemia might be associated with an increased risk of osteoarthritis. BioMed Research International, 3105248. https://doi.org/10.1155/ 2020/3105248 DOI: https://doi.org/10.1155/2020/3105248
Baudart, P., Louati, K., Marcelli, C., Berenbaum, F., & Sellam, J. (2017). Association between osteoarthritis and dyslipidaemia: a systematic literature review and meta-analysis. RMD Open, 3 (2), e000442. https://doi.org/10.1136/rmdopen-2017-000442 DOI: https://doi.org/10.1136/rmdopen-2017-000442
Kwon, D.G., Kim, M.K., Jeon, Y.S., Nam, Y.C., Park, J.S., & Ryu, D.J. (2022). State of the Art: The Immunomodulatory Role of MSCs for Osteoarthritis. International Journal of Molecular Sciences, 23(3), 1618. https://doi.org/10.3390/ijms23031618 DOI: https://doi.org/10.3390/ijms23031618
Cai, X., Yuan, S., Zeng, Y., Wang, C., Yu, N., & Ding, C. (2021). New Trends in Pharmacological Treatments for Osteoarthritis. Frontiers in Pharmacology, 12, 645842. https://doi.org/10.3389/fphar.2021.645842 DOI: https://doi.org/10.3389/fphar.2021.645842
Babinets, L.S., Halabitska, I.M. (2021). Characteristics of joint pain in patients with primary osteoarthritis and comorbid conditions with exocrine pancreatic insufficiency. Lek. Obz., 70 (2), 62-64.
Babinets, L.S., Halabitska, I.M., Kotsaba, Y.Y., Borovyk, I.O., Migenko, B.O., Ryabokon, S. S., & Tsybulska, L. S. (2018). The effect of the proteolisis' system activity for the trophological status of patients with osteoarthrosis and excretory insufficiency of pancreas. Wiadomosci Lekarskie (Warsaw, Poland : 1960), 71 (2 pt 1), 273-276.
Halabitska, I.M., & Babinets, L.S. (2021). Different consequences of the treatment of osteoarthritis in gastrointestinal comorbidity with exocrine pancreatic insufficiency. Family Medicine & Primary Care Review, 23 (4), 422-428. https://doi.org/10.5114/fmpcr.2021. 108207 DOI: https://doi.org/10.5114/fmpcr.2021.108207
Osteoarthritis Guideline Recommendations for the Use of Nonpharmacologic and Pharmacologic Therapies in Osteoarthritis of the Hand, Hip, and Knee American College of Rheumatology 2020. Available from URL: https://www.rheumatology.org/Practice-Quality/Clinical-Support/Clinical-Practice-Guidelines.
Bannuru, R.R., Osani, M.C., Vaysbrot, E.E. (2019). OARSI Guidelines for the non-surgical management of knee, hip, and polyarticular osteoarthritis Osteoarthritis and Cartilage, 27 (11), 1578-1589. https://doi.org/10.1016/j.joca.2019.06.011 DOI: https://doi.org/10.1016/j.joca.2019.06.011
Sakellariou, G., Conaghan, P.G., Zhang, W. (2017). EULAR recommendations for the use of imaging in the clinical management of peripheral joint osteoarthritis. Ann. Rheum. Dis. 76, 1484-1494. https://doi.org/10.1136/annrheumdis-2016-210815 DOI: https://doi.org/10.1136/annrheumdis-2016-210815
Nukala, S., Puvvada, S.R., Luvsannyam, E., Patel, D., & Hamid, P. (2021). Hyperlipidemia and statin use on the progression of osteoarthritis: A systematic review. Cureus, 13 (6), e15999. https://doi.org/10.7759/cureus.15999 DOI: https://doi.org/10.7759/cureus.15999
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Medical and Clinical Chemistry
This work is licensed under a Creative Commons Attribution 4.0 International License.
